Nicorandil in the prevention of cardiac damage and type 4A myocardial infarction with planned percutaneous coronary intervention in patients with atherosclerosis of coronary arteries

Issue: 
8
Year: 
2019

G. Soboleva, MD; R. Gostishchev; A. Rogoza, Doctor of Biological Sciences; T. Kotkina, Candidate of Medical Sciences; Professor A. Samko, MD National Medical Research Center of Cardiology, Moscow

To study the possibility of reducing the risk of intraoperative cardiac damage and 4a type myocardial infarction by administering the oral nicorandil in patients with a stable form of coronary artery disease before planned percutaneous coronary intervention.
Keywords: 
cardiology
nicorandil
coronary angioplasty
coronary artery disease

References: 
  1. Mironova O.Ju. Infarkt miokarda tipa 4a // Ter. arh. – 2014; 9: 102–7 [Mironova O.Yu. Type 4a myocardial infarction // Therapeutic archive. – 2014; 9: 102–7 (in Russ.)].
  2. Zeitouni M., Silvain J., Guedeney P. et al. Periprocedural myocardial infarction and injury in elective coronary stenting // Eur. Heart J. – 2018; 39: 1100–9. DOI: 10.1093/ eurheartj/ehx799.
  3. Alekjan B.G., Grigor'jan A.M., Staferov A.V. i dr. Rentgenendovaskuljarnaja diagnostika i lechenie zabolevanij serdtsa i sosudov v Rossijskoj Federatsii – 2017 god // Endovaskuljarnaja hirurgija. – 2018; 5: 93–240 [Alekyan B., Grigoryan A., Staferov A. et al. Endovascular diagnostics and treatment in the Russian federation (2017) // Russian Journal of Endovascular Surgery. – 2018; 5 (2): 93–240 (in Russ.)]. DOI: 10.24183/2409-4080-2018-5-2-93-240.
  4. Montalescot G., Sechtem U., Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology // Eur. Heart J. – 2013; 34: 2949–3003. DOI: 10.1093/eurheartj/eht296.
  5. Kawai Y., Hisamatsu K., Matsubara H. et al. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon // Eur. Heart J. – 2009; 30: 765–72. DOI: 10.1093/eurheartj/ehp077.
  6. Yang J., Zhang J., Cui W. et al. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention // Anatolian J. Cardiol. – 2015; 15: 125–31. DOI: 10.5152/akd.2014.5207.
  7. Thygesen K., Alpert J., Jaffe A. et al. Fourth universal definition of myocardial infarction // Eur. Heart J. – 2019; 40: 237–69. DOI: 10.1093/eurheartj/ehy462.
  8. Hausenloy D., Yellon D. Preconditioning and postconditioning: underlying and clinical application // Atherosclerosis. – 2009; 204: 334–41. DOI: 10.1016/j.atherosclerosis.2008.10.029.
  9. Hirohata A., Yamamoto K., Hirose E. et al. Nicorandil prevents microvascular dysfunction resulting from PCI in patients with stable angina pectoris: a randomised study // EuroIntervention. – 2014; 9: 1050–6. DOI: 10.4244/EIJV9I9A178.
  10. Pang Z., Zhao W., Yao Z. Cardioprotective Effects of Nicorandil on Coronary Heart Disease Patients Undergoing Elective Percutaneous Coronary Intervention // Med. Sci. Monit. – 2017; 23: 2924–30. DOI: 10.12659/MSM.902324.
  11. Gudnadottir G., Andersen K., Thrainsdottir I. et al. Gender differences in coronary angiography, subsequent interventions, and outcomes among patients with acute coronary syndromes // Am. Heart J. – 2017; 191: 65–74. DOI: 10.1016/j.ahj.2017.06.014.